Achieve Life Sciences Stock Price, News & Analysis

Achieve Life Sciences, Inc. (Nasdaq: ACHV) is described as a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. According to the company’s disclosures, its work centers on smoking cessation and vaping cessation, with an emphasis on addressing the global smoking health and nicotine dependence epidemic.

Achieve reports that it is advancing cytisinicline as a potential treatment of nicotine dependence for smoking cessation in adults, supported by two completed Phase 3 trials (ORCA-2 and ORCA-3) and an open-label long-term safety study (ORCA-OL). The company states that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for cytisinicline for smoking cessation and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 20, 2026. Achieve also notes that it has completed a Phase 2 study of cytisinicline in vaping cessation and has conducted an end-of-Phase 2 meeting with the FDA to support a future vaping indication.

Business focus and development stage

In its news releases, Achieve consistently characterizes itself as a late-stage specialty pharmaceutical company focused on nicotine dependence. Its primary business activity, as described by the company, is the clinical development and planned commercialization of cytisinicline. The company highlights that cytisinicline is an investigational product candidate and has not been approved by the FDA for any indication in the United States.

Achieve reports that its NDA for cytisinicline in smoking cessation is supported by data from more than 2,000 participants in Phase 3 trials, as well as long-term exposure data from the ORCA-OL trial. The company notes that the ORCA-OL trial was designed to meet FDA expectations for cumulative safety data, including at least six months of exposure in hundreds of participants and at least one year of exposure in more than 100 participants, and that the Data Safety Monitoring Committee (DSMC) completed its final review without identifying drug safety concerns.

Cytisinicline and nicotine dependence

Achieve describes cytisinicline as a plant-based (plant-derived) alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Based on the company’s public statements, cytisinicline is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products. Achieve emphasizes that cytisinicline remains an investigational product candidate and is being developed specifically as a treatment of nicotine dependence for smoking cessation, with additional development for vaping cessation.

The company cites published clinical data, including a post hoc analysis of the ORCA-2 and ORCA-3 Phase 3 trials in the journal Thorax, which evaluated cytisinicline in individuals with and without chronic obstructive pulmonary disease (COPD). According to Achieve’s summary of this publication, cytisinicline significantly improved smoking quit rates compared to placebo in adults with COPD and demonstrated a favorable tolerability and safety profile in both COPD and non-COPD subgroups.

Regulatory designations and programs

Achieve reports that cytisinicline has received Breakthrough Therapy designation from the FDA for nicotine e-cigarette or vaping cessation. The company also states that it has been awarded a Commissioner’s National Priority Voucher (CNPV) for cytisinicline for treatment of nicotine dependence associated with e-cigarette or vaping cessation. According to Achieve, this voucher is part of an inaugural FDA program limited to nine therapies and is intended to provide enhanced FDA engagement and expedited review timelines once required materials are submitted.

For the smoking cessation indication, Achieve notes that the FDA’s acceptance of its NDA and assignment of a PDUFA date reflects the agency’s agreement to review cytisinicline as a potential treatment of nicotine dependence for smoking cessation in adults. For vaping cessation, Achieve indicates that the Phase 2 ORCA-V1 trial demonstrated clinical efficacy, and that the agreed Phase 3 trial design (ORCA-V2), together with ORCA-V1, is intended to support a supplemental NDA for a vaping indication.

Clinical program highlights

Across its public communications, Achieve emphasizes several elements of its cytisinicline clinical program:

• Two randomized, placebo-controlled Phase 3 trials (ORCA-2 and ORCA-3) in smoking cessation, which the company states showed significantly higher abstinence rates with cytisinicline compared to placebo.
• The ORCA-OL long-term safety trial, designed to provide extended exposure data in adults seeking to quit smoking or vaping, with participants dosed with 3 mg cytisinicline three times daily and followed for up to one year.
• A Phase 2 trial (ORCA-V1) in nicotine e-cigarette or vaping cessation, in which Achieve reports that participants treated with cytisinicline were more likely to quit using nicotine e-cigarettes or vapes compared to placebo.
• Post hoc analyses in high-risk subgroups, including adults with self-reported COPD, where cytisinicline was associated with improved quit rates and a favorable safety profile.

These clinical activities, as described by Achieve, form the basis of the company’s regulatory submissions and its focus on nicotine dependence as a medical condition.

Public health context cited by the company

In its descriptions of cytisinicline, Achieve references external public health data to frame the need for new nicotine dependence treatments. The company cites estimates that there are approximately 29 million adults in the United States who smoke combustible cigarettes and approximately 17 million adults who use e-cigarettes, along with millions of middle and high school students who report e-cigarette use. Achieve notes that tobacco use is described as a leading cause of preventable death worldwide and in the United States, and that no FDA-approved treatments are indicated specifically as an aid to nicotine e-cigarette cessation.

Within this context, Achieve positions cytisinicline as a potential pharmacologic option for people seeking to quit smoking or vaping, while repeatedly stating that cytisinicline remains investigational and has not been approved by the FDA for any indication.

Capital markets and corporate activity

Achieve Life Sciences, Inc. is listed on Nasdaq under the symbol ACHV. The company has reported entering into capital markets transactions, such as an underwriting agreement for an offering of common stock and accompanying warrants under an effective shelf registration statement on Form S-3. In its SEC filings, Achieve describes the terms of these securities, including common warrants and pre-funded warrants, and notes that net proceeds are expected to support its activities, subject to customary closing conditions.

The company has also reported executive leadership changes and appointments, including the appointment of a Chief Legal Officer and changes in its Chief Medical Officer role, with related compensatory and consulting arrangements disclosed in Form 8-K filings. These filings indicate that Achieve continues to manage its leadership structure as it advances cytisinicline through clinical development and regulatory review.

Company status

Based on the provided SEC filings and news releases, Achieve Life Sciences, Inc. continues to file periodic and current reports and describes itself as a late-stage specialty pharmaceutical company with an active NDA under FDA review. There is no indication in the supplied materials of delisting, deregistration, bankruptcy, or completed merger transactions affecting the ACHV listing.